Kymera is inventing a new generation of small molecule medicines by tackling the root cause of disease with targeted protein degradation.
No named decision-maker yet.
No careers mailbox known
Sep 28
Closed a role Senior Specialist or Manager, Quality Systems · Senior Director, Outcomes, Value & Access crossed 45 days open
Sep 26
Posted 26 roles Senior Manager or Associate Director, Strategic Sourcing, Director, Trial Master File
Sep 25
2 roles crossed 45 days open
Sep 23
2 roles crossed 90 days open
25 open
$278k stated pay, 26 roles
truth B 75 100% stale
Unique ScientificApproach. Accelerated by the discovery capabilities and validated pipeline built at Scorpion Therapeutics (acquired by Lilly in March 2025), Antares pushes scientific boundaries and challenges assumptions to unlock new possibilities for improving patients' lives.
No named decision-maker yet.
Careers mailbox is known
Sep 28
Posted a role Scientist II/Sr. Scientist I, Immunology
Sep 27
Posted 5 roles Principal Scientist/Sr. Principal Scientist, Computational Chemistry & Molecular, Scientist II/Sr. Scientist I, In-Vivo Pharmacology (Must Have Immunology Experie
6 open
$217k stated pay, 5 roles
Kailera is a late clinical-stage biotechnology company advancing a diversified pipeline of GLP-1 therapies to provide options for people living with obesity.
No named decision-maker yet.
Careers mailbox is known
Sep 25
Closed a role Senior Vice President, Program Leadership
Sep 24
Closed a role Associate II, CMC Operations
Sep 23
Senior Vice President, Program Leadership crossed 90 days open
2024
Founded
6 open
$189k stated pay, 5 roles
Vima Therapeutics is advancing a new era in treatment to help people living with movement disorders regain the freedom to move.
No named decision-maker yet.
No careers mailbox known
Synlogic is the leading company advancing therapeutics based on synthetic biology, working at the intersection of biology and engineering to treat disease.
No named decision-maker yet.
Careers mailbox is known
Correctors and Potentiators for Autosomal Dominant Polycystic Kidney Disease (ADPKD). Transforming the Treatment of ADPKD.
Emily Conley · Executive Officer, Director · decision-maker
Thomas Gustafson · Executive Officer · decision-maker
Kevin Bitterman · Director
Anna French · Director
Careers mailbox is known
2025
Team of 20 was 10 · US Form 5500 (plan participants)
Jun 3, 2025
Raised a round Venture round $30M · SEC Form D
2022
Founded
Matchpoint aims to discover and develop precision small molecules that harness the power of covalency to bring new possibilities to the treatment of serious immune disease and cancer.
No named decision-maker yet.
Careers mailbox is known
Sep 27
Moved to Greenhouse
DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless of the underlying cause of inflammation.
Robert Clarke · Executive Officer, Director · decision-maker
Frazer Morgan · Executive Officer · decision-maker
Roger Heerman · Executive Officer · decision-maker
Bram Vanparys · Director
No careers mailbox known
Jun 29
Board appointment Kinaset Therapeutics Appoints Daniel G. Welch as Board Chair and David Lubner as Independent Director and Audit Committee Chair · morningstar.com
Jul 5, 2022
Raised a round Venture round $28.5M · SEC Form D
2020
Founded
No named decision-maker yet.
Careers mailbox is known
Akero Therapeutics is a clinical-stage company developing transformational therapies for people with metabolic dysfunction-associated steatohepatitis (MASH).
No named decision-maker yet.
No careers mailbox known
Sep 27
Moved to Greenhouse
Our Science Platform Pipeline REM-422 About Us Our Story Our People Our Investors Our Partners Join Us News News Presentations Press Releases Publications Clinical Trials Contact Meet Remix™ Remix launched with a vision to transform patient's lives through modulation of RNA processing.
No named decision-maker yet.
Careers mailbox is known
Sep 27
Posted a role Vice President, Clinical Development
Sep 18
Vice President, Clinical Development crossed 90 days open
1 open
$358k stated pay, 1 roles
Discover how Day One Biopharmaceuticals is disrupting the status quo of traditional drug development to bring new medicines to children and adults with cancer.
No named decision-maker yet.
Careers mailbox is known
Sep 26
Moved to Greenhouse
Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent's lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
No named decision-maker yet.
Careers mailbox is known
Sep 29
Posted a role Scientist, DMPK (BioAnalytical and Medical Writing)
Sep 26
Posted 6 roles Research Investigator, Computational Chemistry, Principal Scientist, Computational Chemistry
Pioneering a new class of allosteric medicines for the treatment of autoimmune disease. At HotSpot Therapeutics, we are pioneering a new approach to allosteric drug discovery by unlocking the on/off switches on proteins called "natural hotspots" to enable differentiated medicines for patients.
No named decision-maker yet.
Careers mailbox is known
Diagonal Therapeutics pioneers a new era in medicine by advancing clustering antibody therapeutics targeting the root causes of devastating diseases.
No named decision-maker yet.
Careers mailbox is known
Affinia Therapeutics is expanding what's possible in adeno-associated virus (AAV) gene therapy today and bringing transformative medicines for people.
No named decision-maker yet.
Careers mailbox is known
Sep 26
Moved to Greenhouse
Our purpose is. Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia.
Thomas Johnson · Executive Officer, Director · decision-maker
Michael Young · Executive Officer · decision-maker
Allison August · Executive Officer · decision-maker
Paul Antinori · Executive Officer · decision-maker
No careers mailbox known
Dec 14, 2023
Raised a round Venture round $37.5M · SEC Form D
2020
Founded
AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet need.
No named decision-maker yet.
Careers mailbox is known
Sep 26
Posted a role Director of Biostatistics
